Related Experiment Video
Updated: Aug 2, 2026
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Angiotensin receptor blockers: evidence for preserving target organs
P Carson1, T Giles, M Higginbotham
1Department of Cardiology, Veterans Affairs Medical Center, Washington, DC, USA.
Insights
Angiotensin receptor blockers (ARBs) offer a targeted approach to managing hypertension by blocking the renin-angiotensin system (RAS). Clinical trials demonstrate their effectiveness in protecting organs and reversing cardiovascular damage.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Hypertension is a global health issue with current treatments facing challenges in patient compliance and complete blood pressure normalization.
- Chronic hypertension leads to cardiovascular remodeling, which existing therapies may not fully prevent or reverse.
- Blockade of the renin-angiotensin system (RAS) is a key strategy for hypertension and heart failure management.
Purpose of the Study:
- To review clinical trials evaluating the efficacy of angiotensin receptor blockers (ARBs) in cardiovascular protection.
- To compare the mechanisms and outcomes of ACE inhibitors and ARBs in managing hypertension and its complications.
- To highlight the role of ARBs in preserving target-organ function and reversing cardiovascular remodeling.
Main Methods:
- Review of clinical trials and experimental data on antihypertensive medications.
- Analysis of the renin-angiotensin system (RAS) pathways and the mechanisms of action for ACE inhibitors and ARBs.
- Evaluation of data on organ protection (myocardium, blood vessels, renal vasculature) and cardiovascular remodeling.
Main Results:
- Angiotensin-converting enzyme (ACE) inhibitors block one RAS pathway and affect bradykinin, potentially causing cough.
- Angiotensin receptor blockers (ARBs) selectively block the Ang II type 1 (AT1) receptor, offering specificity and fewer side effects.
- Clinical trials confirm ARBs' efficacy in preserving target-organ function and reversing cardiovascular remodeling.
- Combined therapy with ARBs and ACE inhibitors may provide maximal benefit in Ang II blockade.
Conclusions:
- ARBs are effective and specific agents for managing hypertension and protecting against cardiovascular damage.
- ARBs demonstrate significant benefits in preserving myocardial, vascular, and renal function.
- The review supports the use of ARBs, and potentially combination therapy, for comprehensive management of hypertension and related cardiovascular remodeling.
Abstract:
Hypertension is a major problem throughout the developed world. Although current antihypertensive treatment regimens reduce morbidity and mortality, patients are often noncompliant, and medications may not completely normalize blood pressure. As a result, current therapy frequently does not prevent or reverse the cardiovascular remodeling that often occurs when blood pressure is chronically elevated. Blockade of the renin-angiotensin system (RAS) is effective in controlling hypertension and treating congestive heart failure. Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) inhibit the activity of the RAS, but these two classes of antihypertensive medications have different mechanisms of action and different pharmacologic profiles. Angiotensin-converting enzyme inhibitors block a single pathway in the production of angiotensin II (Ang II). In addition, angiotensin I is not the only substrate for ACE. The ACE inhibitors also block the degradation of bradykinin that may have potential benefits in cardiovascular disease. Bradykinin is, however, the presumed cause of cough associated with ACE inhibitor therapy. Data from clinical trials on ACE inhibitors serve to support the involvement of the RAS in the development of cardiovascular disease. Angiotensin receptor blockers act distally in the RAS to block the Ang II type 1 (AT1) receptor selectively. Thus, ARBs are more specific agents and avoid many side effects. Experimental and clinical trials have documented the efficacy of ARBs in preserving target-organ function and reversing cardiovascular remodeling. In some instances, maximal benefit may be obtained with Ang II blockade using both ARBs and ACE inhibitors. This review describes clinical trials that document the efficacy of ARBs in protecting the myocardium, blood vessels, and renal vasculature.
Related Concept Videos
01:17Antihypertensive Drugs: Action of β1 Blockers
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...